Eli Lilly spokesperson says company is carefully evaluating FDA drug-safety communication for GLP-1 RA and will respond promptly
Observed price moves
- LLY+0.36%10 min after this headline
MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.